Reduced intensity conditioning regimens lead to an increasing use of allogeneic hematopoietic cell transplantation (HCT) in elderly patients. We retrospectively analyzed 151 patients aged ⩾ 60 receiving allogeneic HCT 2000-2012 at our center. Median age was 66 years. Kaplan-Meier estimated 3-year OS was 42% with a median follow-up of 38 months. Cumulative incidences of progression and non-relapse mortality after 3 years were 38 and 24%. OS was better in the group of patients 465 years with a Kaplan-Meier estimated OS of 50% vs 34%, P = 0.060. We observed a significant influence of donor age (o 50 years: 53% vs 450 years: 30%, P = 0.017) and gender match (matched: 57% vs mismatched: 32%, P = 0.007) on outcome. The use of a matched related donor was inferior compared with a matched or mismatched unrelated donor (19% vs 47%, P = 0.015). On multivariate analysis there was an increased hazard ratio for a non-gender-matched HLA-matched-related donor (hazard ratio 3.23, 95% confidence interval 1.55-6.74, P = 0.002). Age had no significant impact on OS (P = 0.414). In conclusion, the data suggest that older age alone has no negative impact on the outcome of allogeneic HCT. Transplant decision should be tailored to disease risk and patient performance status rather than age.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) offers a potentially curative therapy for various hematological diseases. Historically, allogeneic HCT has been offered to patients with good performance status and below the age of 60 because of unacceptable toxicity and treatment-related mortality if performed in elderly and comorbid patients. However, the peak incidence of most hematopoietic malignancies is above 60 years of age. The incidence of AML is 10-fold greater in patients of 65 years of age compared with the incidence in patients aged 20-44 years. 1, 2 In a report of the German Acute Myeloid Leukemia Cooperative Group age ⩾ 60 years was a significant poor prognostic factor for CR, remission duration, OS and relapse-free survival. 3 The negative impact of age ⩾ 60 years was also reported in patients with Non-Hodgkin-lymphoma, ALL and Hodgkin lymphoma. [4] [5] [6] [7] Among the reasons for the inferior survival in elderly patients are increased chemotherapy-related toxicities and adverse disease biology. 8 The introduction of reduced intensity conditioning (RIC) regimens in allogeneic HCT allows the use of this treatment even in older, comorbid or heavily pretreated patients and therefore enables a curative therapeutic option in patients who are not the candidates for HCT using a myeloablative conditioning. The use of RIC results in a major reduction of transplant-related toxicity and mortality, 9 and allows allogeneic HCT even in elderly patients beyond 70 years of age.
There is increasing evidence that using RIC, patient age alone may not be an independent risk factor for survival after allogeneic HCT. 10 We therefore retrospectively analyzed 151 patients aged ⩾ 60 who received allogeneic HCT between 2000 and 2012 at our institution.
PATIENTS AND METHODS

Patient population
We searched our institutional database for patients aged ⩾ 60 years treated with allogeneic HCT between 2000 and 2012. Details on patient characteristics and course of disease were confirmed by chart review. Comorbidities were retrospectively analyzed using the HCT-specific comorbidity index (HCT-CI). 11 Patients were classified in different disease risk categories as defined by Armand et al.
12
Response and disease stage were assessed using the criteria of the international working group. 13 Acute GVHD was graded according to the Glucksberg criteria.
14 Chronic GVHD was graded according to the revised Seattle classification. 15 
HLA typing and donors
Patients and donors were tested for HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DRQ1 by high-resolution molecular typing methods. 10/10 HLAmatched related (MRD) and unrelated (MUD) or 1-2 antigen/allele mismatched related (MMRD) or unrelated (MMUD) donors were used. The grafts consisted of G-CSF-mobilized (Lenograstim, Granocyte, Chugai Pharma, 16 Germany, at a dose of 2 × 5 g/kg/day for 5 days)PBSC.
Conditioning, transplantation and GVHD prophylaxis
Conditioning regimens were grouped as RIC and non-myeloablative (NMA) according to the recommendations of the CIBMTR in Giralt and colleagues 16 and Bacicalupo and colleagues 17 in respect to toxicities and expected length of aplasia.
On day 0, all patients received fresh or cryopreserved PBSC. CsA or tacrolimus (plasma level 200-250 ng/mL and 10-15 ng/mL, respectively, start day -1) combined with mycophenolate mofetil (1 g twice daily, start day +1) or short course MTX (day 1, 3, 6 and 11) were used as GVHD prophylaxis. In most patients with MUD anti-thymocyte globuline ATG-Fresenius (Neovii Biotech GmbH, Gräfelfing, Germany) or Thymoglobuline (Sanofi-Aventis GmbH, Frankfurt, Germany) was added.
Monitoring of patients for engraftment, disease and chimerism Engraftment was analyzed by peripheral blood counts and chimerism analysis. Engraftment of neutrophils was defined as the first of three consecutive days with the ANC over 500 cells/μL. Engraftment of platelets was defined as the first of three consecutive days with consistently more than 20 000 cells/μL without a transfusion before. Chimerism of donor cells was analyzed in mononuclear cells using microsatellite markers as described in detail previously. 18 
Statistical analysis
For statistical analysis SAS version 9.2 (SAS Institute, Cary, NC, USA) biostatistical software was used. Actuarial curves were estimated according to the Kaplan-Meier method, the log-rank test was used for the comparison of Kaplan-Meier estimates and corresponding 95% confidence intervals between different groups of patients. Univariate and multivariate Cox regression was used to estimate hazard ratios and corresponding 95% confidence intervals. OS was measured as the number of months from transplantation to death from any cause. Patients who were still alive at follow-up were censored at the last follow-up date. Time to non-relapse mortality (NRM) included only deceased patients who died without preceding relapse. Cumulative incidence of NRM and relapse/progression were calculated using a SAS macro (www.uhnres.utoronto.ca/labs/hill/datasets/Pintilie/SASma cros/compcif.txt) based on Pepe/Mori. 19 Progression/relapse (PFS) was calculated as the number of months from HCT until relapse/progression. Patients without evidence for relapse/progression were censored at last follow-up date or date of death. Risk factors for OS were evaluated using univariate comparisons and Cox regression. The following factors were included in the regression models: age, HCT-CI, disease risk index, donor age, gender match, HLA-Status (MRD vs MUD vs MMUD), intensity of conditioning (RIC vs NMA), CMV match, ATG. A multivariate Cox regression for OS was estimated. The final model includes only factors that had P-values o0.1. Proportional hazard assumption was checked with log (survival) vs log of survival time graphes. Interaction factors (multiplicity or additivity) were checked and included in the final model for factors that had P-values o0.1. All P-values are two-sided without adjustments for multiple testing.
RESULTS
Patients, disease status and donors
Patient characteristics are summarized in Tables 1 and 2 . Median age of patients studied was 66 years. Diagnoses were AML (n = 91), ALL (n = 1), Non-Hodgkin lymphoma (NHL, n = 11), multiple myeloma (n = 8), CML (n = 3), myelodysplastic syndrome (MDS, n = 23), chronic lymphocytic leukemia (CLL, n = 3), primary myelofibrosis (n = 10) and aplastic anemia (n = 1). Data to classify the patients according to their cytogenetic and molecular markers were available in 108 and 63 patients, respectively. At the time of HCT 56 patients were in CR and 95 patients were transplanted in PR, respectively. According to Armand et al.
12 the disease risk index was calculated for each patient. Most of the patients were in the intermediate disease risk group (101/ 151; 67%), followed by high (28/151; 11%), very high (13/151; 9%) and low risk (9/151; 6%). Results of univariate analysis are summarized in Table 2 . OS was similar in the different risk categories with 43% (low/intermediate risk) vs 41% (high/very high), P = 0.514.
Using the HCT-comorbidity index we found a median index of 2.5 (range, 0-9, n = 144). Categorizing the patients in two groups according to the HCT-CI (HCT-CI = 0, HCT-CI40) no difference in Kaplan-Meier estimated OS could be confirmed (P = 0.181) ( Table 3) .
The number of patients transplanted from a MRD was small compared with MUD or MMUD (MRD = 23, MUD = 70, MMUD = 57, MMRD = 1). The median age of donor was 38 years (range 18-72, information available in 129 patients) and most of the donors were male (n = 83, information available in 132 donors), resulting in a gender match in 80 transplanted patients. Younger donor age (⩽50 years: 53% vs 450 years: 30%, P = 0.017) as well as gender match (matched: 57% vs mismatched: 32%, P = 0.007) had a positive influence on survival. The use of a matched related donor was significantly inferior compared with a matched or mismatched unrelated donor (19% vs 47%, P = 0.015) ( Table 3) . CMV status was matched in 100 patients. No inferior survival could be found for these patients compared with CMV mismatched patients with 37% vs 53%, P = 0.104. Abbreviations: AA = aplastic leukemia; DRI = disease risk index; MDS = myelodysplastic syndrome; MM = multiple myeloma; MRD = matched related donor; MUD = matched unrelated donor; MMUD = mismatched unrelated donor; NHL = non-Hodgkin-lymphoma; PMF = primary myelofibrosis.
Influence of age on outcome after HCT B Federmann et al
Conditioning, engraftment and chimerism Patients were transplanted using RIC (n = 114) or NMA (n = 37) (conditioning regimens are listed in Table 2 ). ATG was used in 109/151 patients. No association of use of ATG was found concerning OS (3-year-OS 38 vs 51% P = 0.275). There was no advantage in OS using NMA compared with RIC (3-year-OS 40 vs 43% P = 0.634). All but 10 patients had engraftment of neutrophils. These 10 patients died prior engraftment due to relapse or NRM. Median time to neutrophil engraftment was 17 days (range, 7-50). Engraftment of platelets occurred in all but in18 patients after a median time of 17 days (range, 7-577).
Disease response and OS Current OS is 67/151 patients (44%) with a median follow-up of 38 months (range, 2-95 months), resulting in a 3-year-OS of 42% (Figure 1 ). Comparing the subgroups of patients aged 60-65 years and 466 years respectively, the data suggest an advantage in the survival for the older patient group with a 3-year-OS of 50% vs 34%, P = 0.06 (Table 3 ). In the older age cohort 28 patients were ⩾ 70 years of age. The proportion of patients dying due to relapse was 26% (39/151 patients). Cumulative incidence of relapse/progression adjusted for NRM as competing risk at 3 years was 35% (Figure 2 ).
In the multivariate Cox regression only HLA status and gender match were identified to be independent risk factors for OS. Further analysis showed an additive influence of both factors. The final model including this additive interaction and continuous age suggested an increased hazard ratio for a non-gender-matched HLA-matched-related donor (HR 3.23, 95% CI 1.55-6.74, P = 0.002) compared with gender-matched HLA-non-matched-related donor. In a multivariate analysis no influence of age on survival (P = 0.414) could be found (Table 4) .
GVHD and NRM Incidence of acute GVHD ⩾ grade II was 14/151 patients (9%) (grade II = 9, grade III = 4 and grade IV = 1). Chronic GVHD was observed in 66/151 (44%) patients (limited = 39, extensive = 26). In the group of patients ⩾ 70 years we observed no acute GVHD but chronic GVHD in 39% (11/28) of the patients. Seven patients developed a limited and four patients an extensive chronic GVHD.
NRM was 30% (45/151 patients) in the whole cohort. Causes of death were infections (n = 14), GVHD (n = 11) multi-organ-failure (n = 14) and others (n = 6). In the group of patients aged ⩾ 70 years 14% (4/28) died due to NRM, three of them caused by infection and one because of multi-organ-failure. Cumulative incidence of Abbreviations: ATG = anti-thymocyte globulin; NMA = non-myeloablative conditioning; plts = platelets; RIC = reduced intensity conditioning. Abbreviations: ATG = anti-thymocyte globulin; CI = confidence interval; DRI = disease risk index; HCT-CI = hematopoietic cell transplantationspecific comorbidity index; NMA = non-myeloablatove conditioning; RIC = reduced intensity conditioning. Influence of age on outcome after HCT B Federmann et al NRM at 3 years adjusted for relapse as competing risk was 24% ( Figure 3) .
DISCUSSION
With the growing median age of the population the incidence of hematologic malignancies increases. In contrast to younger adults where allogeneic HCT is an established treatment option, this potentially curative treatment modality is still rarely used in older patients, particularly in patients aged ⩾ 70 years. To assess the impact of age on the outcome and efficiency of RIC allogeneic HCT in our own center we performed this retrospective, single center study in patients receiving HCT ⩾ 60 years of age. With a Kaplan-Meier estimated 3-year OS of 42%, our data are comparable with published results, implicating that other factors than age should be taken into consideration deciding whether to proceed to allogeneic HCT. This confirms the results of prior reports such as by Sorror et al. 10 with the largest patient cohort of 372 patients between 60 and 76 years of age, who observed an OS of 35% with 5 years follow-up. The patients reported by Sorror et al. were transplanted after RIC with low-dose TBI alone or in combination with Fludarabine. They are therefore comparable to the NMA-conditioning cohort in our study. Koreth et al. 20 analyzed 158 patients (range, 60-71 years) after allogeneic HCT with RIC conditioning observing a 2-year-OS of 49% in patients between 60 and 64 years and 42% in patients over 65 years. A second study of Koreth et al. 20 analyzed the use of RIC in a cohort of patients ⩾ 60 years and demonstrated the feasibility of the procedure in elderly patients, as well as the lacking influence of age on survival after HCT. 20 Another study of the EBMT group including 1333 patients between 50 and 74 years again shows that older age had no significant influence on the outcome. 21 Data of the CIBMTR in 1080 patients older than 40 years demonstrated in multivariate analysis that chronological age did not influence NRM, relapse or rate of GVHD, and therefore lead to the conclusion that age alone should not be a contraindication for allogeneic HCT. 22 In a recent published study of Brunner et al. 13 describing patients over the age of 70 years, a 2-year-OS of 39% was found with a median follow-up of 21 months of patients alive. In our study the subgroup of patients ⩾ 66 years had a comparable outcome with a 3-year-OS of 50% with a high proportion of patients ⩾ 70 years of age (n = 28).
As comorbidities may have a significant negative influence on outcome after allogeneic HCT 23, 24 evaluation of the HCT-CI 11 should be applied for comparison of results of the respective patient cohorts in different studies. In our study the HCT-CI was a median of 2.5, which is slightly higher than in other published studies and has to be kept in mind when comparing the OS rates. 12, 13 Various levels of intensity of RIC regimens have been reported. We therefore grouped the intensity of conditioning in our study according to expected toxicities and length of aplasia in RIC and NMA. 16, 17 In the most published studies the intensity of conditioning was comparable to our regimens. 10, 20 In elderly patients MRD are mostly of similar advanced age as the recipient. Given age and potential comorbidities the choice between an older MRD and a younger MUD is an unresolved and ongoing discussion. Some studies claim an inferior outcome to be associated with increased donor age. 25 In a study of Kroger et al.
26
who analyzed 719 elderly patients with MDS, younger MUDs o 30 years of age remained a significant factor for improved survival in comparison with MRD. In the present study we observed an advantage in survival with MUD, which has been reported before after NMA HCT. 25 This may be related to a more pronounced GVL NRM adjusted for competitive risk progression Figure 3 . Analysis of NRM adjusted for competitive risk progression.
Influence of age on outcome after HCT B Federmann et al effect after MUD, but the patient number in our study is too small to draw any definitive conclusions. The incidence of GVHD increases with age and may lead to an impaired outcome and quality of life. [27] [28] [29] In our study, the incidence of GVHD was low and comparable to the study of Koreth et al. 20 who reported 19.6% (9% in our study) for acute and 45.9% (44% in our study) for chronic GVHD, respectively.
On uni-and multivariate analysis, age even 465 years had no negative influence on survival. This suggests that higher age alone should not be an exclusion criterion for allogeneic HCT. Of note, as a line of caution, the present study being a single center analysis is susceptible to a selection bias regarding donor and patient selection. In addition one has to note the long observation period from 2000 to 2012, which could bias the results because of a further development in supportive care, as well as the increasing proportion of older patients treated with allogeneic transplantation.
In conclusion, our data support previous reports that older age alone has no negative impact on outcome of allogeneic HCT. The regimen used should be tailored to disease risk and patient performance status rather than age. There is a need for prospective clinical trials to further identify subgroups of patients benefiting most from allogeneic HCT.
